Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes
Key facts
- Where
- Seongnam-si, South KoreaSee the site
Where in South Korea
- Seoul National University Bundang HospitalSeongnam-si, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chong Kun Dang Pharmaceutical
- Trial code
- NCT06838286
- Record updated
- 30 September 2026
- Original description
A multicenter, prospective, non-interventional observation study to evaluate the safety and effectiveness of OAD triple therapy in Korean Type 2 diabetic mellitus patients.Read full original descriptionShow less
A Multicenter, Prospective, Non-interventional Observation Study to Evaluate the Safety and Effectiveness of OAD Triple Therapy in Korean Type 2 Diabetic Mellitus Patients
A multicenter, prospective, non-interventional observation study to evaluate the safety and effectiveness of OAD triple therapy in Korean Type 2 diabetic mellitus patients.
Inclusion: Patients with type 2 diabetes who are 19 years of age or older at the time of enrollment; Continued DPP-4i or SGLT-2i oral hypoglycemic combination therapy with metformin for at least 8 weeks prior to enrollment; 7.0% ≤ HbA1c < 10.0% based on laboratory tests performed within 4 weeks of enrollment; Voluntarily give written informed consent after being told about the study.
Exclusion: Patients receiving concomitant therapy with 3 or more oral hypoglycemic agents within 8 weeks of enrollment; Requiring treatment with insulin, GLP-1, etc. in addition to oral hypoglycemic agents during the study; Patients who are contraindicated by any of the "Precautions for Use" in the license for the drug being administered during the study, given the observational nature of the study under routine practice; Patients with a history of hypersensitivity to the investigational drug or any of its components or excipients; Patients with type 1 diabetes and secondary diabetes; End-stage renal disease and hemodialysis patients; diabetic ketoacidosis Patients; Pregnant and lactating women; Anyone else deemed by the investigator to be unsuitable for participation in the study.